|
US4582797A
(en)
*
|
1980-09-25 |
1986-04-15 |
The Salk Institute For Biological Studies |
Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
|
|
DE3105150A1
(de)
*
|
1981-02-12 |
1982-08-19 |
Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg |
Herstellung von anti-t-lymphozyten-globulin.
|
|
US4474893A
(en)
*
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US4657852A
(en)
*
|
1982-04-02 |
1987-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for B cell typing of total human lymphocyte sample
|
|
US4471056A
(en)
*
|
1982-04-02 |
1984-09-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for HLA-DR typing of total human lymphocyte sample
|
|
US4511662A
(en)
*
|
1982-06-18 |
1985-04-16 |
Bio-Rad Laboratories, Inc. |
Simultaneous assay for T and B lymphocyte populations and subpopulations
|
|
US4443427A
(en)
*
|
1982-06-21 |
1984-04-17 |
Sidney Farber Cancer Institute, Inc. |
Monoclonal antibody
|
|
US4500637A
(en)
*
|
1982-07-19 |
1985-02-19 |
The United States Of America As Represented By The Department Of Health And Human Services |
Prevention of graft versus host disease following bone marrow transplantation
|
|
US4714613A
(en)
*
|
1982-09-30 |
1987-12-22 |
The Albert Einstein College Of Medicine Of Yeshiva University |
Method of suppressing cell growth by immunotherapy
|
|
US4550086A
(en)
*
|
1983-02-16 |
1985-10-29 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that recognize human T cells
|
|
US4579827A
(en)
*
|
1983-03-11 |
1986-04-01 |
Sloan-Kettering Institute For Cancer Research |
Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
|
|
US4797475A
(en)
*
|
1983-05-20 |
1989-01-10 |
The Regents Of The University Of California |
Method and composition for isolating white cell elements
|
|
US4645738A
(en)
*
|
1983-09-30 |
1987-02-24 |
Memorial Sloan-Kettering Institute Cancer Center |
Method for differential diagnosis of T cell leukemias using monoclonal antibodies
|
|
US4468346A
(en)
*
|
1983-10-27 |
1984-08-28 |
The United States Of America As Represented By The Secretary Of Agriculture |
Monoclonal antibodies to porcine immunoglobulins
|
|
JPS60231699A
(ja)
*
|
1983-11-09 |
1985-11-18 |
Aichiken |
正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
|
|
US4672044A
(en)
*
|
1984-08-24 |
1987-06-09 |
Scripps Clinic & Research Foundation |
Murine monoclonal antibody combining site to human C3b receptor (CR1)
|
|
US4661446A
(en)
*
|
1985-02-19 |
1987-04-28 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies and method of immunizing therewith
|
|
US5431897A
(en)
*
|
1985-04-19 |
1995-07-11 |
Sloan-Kettering Institute For Cancer Research |
Method of imaging colorectal carcinoma lesion and composition for use therein
|
|
US5091178A
(en)
*
|
1986-02-21 |
1992-02-25 |
Oncogen |
Tumor therapy with biologically active anti-tumor antibodies
|
|
US4970299A
(en)
*
|
1986-07-03 |
1990-11-13 |
Sloan-Kettering Institute For Cancer Research |
Monoclonal antibodies selective for prostate cancer
|
|
EP0395669A4
(en)
*
|
1987-10-16 |
1991-01-16 |
Biomedical Systems Limited |
Mouse monoclonal antibodies raised to the t-cell line hsb-2 and t-cell chronic lymphocytic leukemia (t-cll) cells react with normal human t and b lymphocytes and monocytes
|
|
US5601819A
(en)
*
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
IL92382A
(en)
*
|
1988-11-23 |
1994-12-29 |
Univ Michigan |
Use of a ligand specific for CD28 in the manufacture of medicament
|
|
JPH0291833U
(no)
*
|
1988-12-29 |
1990-07-20 |
|
|
|
JPH0277212U
(no)
*
|
1989-01-25 |
1990-06-13 |
|
|
|
US6406696B1
(en)
|
1989-10-27 |
2002-06-18 |
Tolerance Therapeutics, Inc. |
Methods of stimulating the immune system with anti-CD3 antibodies
|
|
CA2071478A1
(en)
*
|
1989-10-27 |
1991-04-28 |
Jeffery A. Bluestone |
Methods and compositions for promoting immunopotentiation
|
|
JPH0420550U
(no)
*
|
1990-06-11 |
1992-02-20 |
|
|
|
US5444155A
(en)
*
|
1991-09-10 |
1995-08-22 |
The Scripps Research Institute |
Molecules with antibody combining sites that induce asymmetry
|
|
US5250426A
(en)
*
|
1991-10-22 |
1993-10-05 |
The Scripps Research Institute |
Molecules with antibody combining sites that induce asymmetry
|
|
US6491916B1
(en)
|
1994-06-01 |
2002-12-10 |
Tolerance Therapeutics, Inc. |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
|
|
US20030108548A1
(en)
*
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU692465B2
(en)
*
|
1993-09-03 |
1998-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
Monoclonal antibody that recognizes interstitial cell surface antigen
|
|
GB9513733D0
(en)
*
|
1995-07-05 |
1995-09-06 |
Univ Bristol |
Therapeutic agents
|
|
JP2000503003A
(ja)
|
1995-12-22 |
2000-03-14 |
イムノメディクス，インコーポレイテッド |
多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
|
|
ATE424410T1
(de)
|
1996-08-30 |
2009-03-15 |
Human Genome Sciences Inc |
Interleukin-19.
|
|
US6498006B2
(en)
|
1997-11-24 |
2002-12-24 |
Johnson T. Wong |
Methods for treatment of HIV and other infections using A T cell or viral activator and anti-retroviral combination therapy
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
US7678836B2
(en)
*
|
1999-11-04 |
2010-03-16 |
Fxs Ventures, Llc |
Method for rendering a contact lens wettable
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US8557868B2
(en)
*
|
2000-11-04 |
2013-10-15 |
Fxs Ventures, Llc |
Ophthalmic and contact lens solutions using low molecular weight amines
|
|
US20070110782A1
(en)
*
|
2000-11-08 |
2007-05-17 |
Fxs Ventures, Llc |
L-histidine in ophthalmic solutions
|
|
CN1212847C
(zh)
*
|
2000-11-08 |
2005-08-03 |
生物概念实验室 |
含有维生素b系列的改进的眼科和隐型眼镜用溶液
|
|
PT1339418E
(pt)
*
|
2000-11-08 |
2009-10-30 |
Fxs Ventures Llc |
Soluções oftálmicas e para lentes de contacto melhoradas contendo sacarídeos simples como intensificadores de conservação
|
|
US20060127496A1
(en)
*
|
2000-11-08 |
2006-06-15 |
Bioconcept Laboratories |
L-histidine in ophthalmic solutions
|
|
US9492582B2
(en)
*
|
2000-11-08 |
2016-11-15 |
Fxs Ventures, Llc |
Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
|
|
US20060148665A1
(en)
*
|
2000-11-08 |
2006-07-06 |
Bioconcept Laboratories |
Ophthalmic and contact lens solutions containing forms of vitamin b
|
|
US9308264B2
(en)
|
2000-11-08 |
2016-04-12 |
Fxs Ventures, Llc |
Ophthalmic contact lens solutions containing forms of vitamin B
|
|
US20070104744A1
(en)
*
|
2000-11-08 |
2007-05-10 |
Fxs Ventures, Llc |
Ophthalmic and contact lens solutions containing forms of vitamin b
|
|
RU2179862C1
(ru)
*
|
2000-12-26 |
2002-02-27 |
Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" |
Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
|
|
US7939501B2
(en)
*
|
2003-04-15 |
2011-05-10 |
Smith Francis X |
Ophthalmic and contact lens solutions containing peptides as preservative
|
|
US8076459B2
(en)
*
|
2003-10-16 |
2011-12-13 |
Micromet Ag |
Multispecfic deimmunized CD3-binders
|
|
EP2397189B1
(en)
|
2003-11-14 |
2015-03-18 |
Brigham and Women's Hospital, Inc. |
Methods of modulating immunity
|
|
EP1904105A4
(en)
*
|
2005-07-11 |
2010-02-17 |
Macrogenics Inc |
METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES WITH IMMUNOSUPPRESSIVE MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY
|
|
SG10201504662WA
(en)
*
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
|
EP2094302A4
(en)
*
|
2006-12-21 |
2010-12-08 |
Macrogenics Inc |
METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY
|
|
JP6193570B2
(ja)
|
2009-07-17 |
2017-09-13 |
バイオアトラ、エルエルシー |
産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化
|
|
AU2011246893A1
(en)
|
2010-04-29 |
2012-11-08 |
Hadasit Medical Research Service And Development Co. Ltd. |
Methods and compositions for treating hepatitis with anti-CD3 immune molecule therapy
|
|
CA2804746C
(en)
|
2010-07-16 |
2022-01-11 |
Jay M. Short |
Novel methods of protein evolution
|
|
WO2012066058A1
(en)
|
2010-11-16 |
2012-05-24 |
Boehringer Ingelheim International Gmbh |
Agents and methods for treating diseases that correlate with bcma expression
|
|
CN105924519B
(zh)
|
2010-12-31 |
2019-08-23 |
生物蛋白有限公司 |
全面单克隆抗体产生
|
|
WO2012092374A2
(en)
|
2010-12-31 |
2012-07-05 |
Short Jay M |
Express humanization of antibodies
|
|
CA2865033C
(en)
|
2012-02-23 |
2021-11-02 |
Stage Cell Therapeutics Gmbh |
Chromatographic isolation of cells and other complex biological materials
|
|
KR102023401B1
(ko)
|
2012-05-10 |
2019-11-04 |
바이오아트라, 엘엘씨 |
다중-특이적 모노클로날 항체
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
US11293929B2
(en)
|
2014-01-07 |
2022-04-05 |
Bioatla, Inc. |
Proteins targeting orthologs
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
KR102459384B1
(ko)
|
2014-04-16 |
2022-10-26 |
주노 테라퓨틱스 게엠베하 |
세포 집단의 증대를 위한 방법, 키트 및 장치
|
|
KR20220136455A
(ko)
|
2014-04-23 |
2022-10-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법
|
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
PT3699198T
(pt)
|
2014-11-17 |
2025-04-29 |
Regeneron Pharma |
Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
|
|
KR102680151B1
(ko)
|
2015-01-23 |
2024-07-03 |
사노피 |
항-ｃｄ3 항체, 항-ｃｄ123 항체, 및 ｃｄ3 및/또는 ｃｄ123에 특이적으로 결합하는 이중특이적 항체
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
|
JP7195141B2
(ja)
|
2015-10-22 |
2022-12-23 |
ジュノ セラピューティクス ゲーエムベーハー |
形質導入のための方法、キット、作用物質および装置
|
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
DK3411065T3
(da)
|
2016-02-05 |
2021-07-05 |
Orionis Biosciences BV |
Clec9a-bindingsmidler
|
|
TWI790206B
(zh)
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
ES3038614T3
(en)
|
2017-04-27 |
2025-10-14 |
Juno Therapeutics Inc |
Oligomeric particle reagents and methods of use thereof
|
|
CN113474450A
(zh)
|
2018-08-09 |
2021-10-01 |
朱诺治疗学股份有限公司 |
产生工程化细胞的方法以及所述工程化细胞的组合物
|
|
MX2021005013A
(es)
|
2018-10-31 |
2021-07-21 |
Juno Therapeutics Gmbh |
Métodos para la selección y estimulación de células y aparatos para los mismos.
|
|
ES2968737T3
(es)
|
2018-11-06 |
2024-05-13 |
Juno Therapeutics Inc |
Proceso para producir células T manipuladas genéticamente
|
|
US20220348660A1
(en)
|
2019-10-02 |
2022-11-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of adult t-cell leukemia/lymphoma
|
|
CA3159380A1
(en)
|
2019-10-30 |
2021-05-06 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
|
WO2021163391A1
(en)
|
2020-02-12 |
2021-08-19 |
Juno Therapeutics, Inc. |
Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
|
JP2023519099A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
|
|
IL296276A
(en)
|
2020-03-10 |
2022-11-01 |
Tiziana Life Sciences Plc |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
AU2021291029A1
(en)
|
2020-06-17 |
2022-11-03 |
Tiziana Life Sciences Plc |
Compositions and methods for augmenting chimeric antigen receptor (CAR) T cell therapies
|
|
EP4188440A2
(en)
|
2020-07-30 |
2023-06-07 |
Tiziana Life Sciences PLC |
Cd-3 antibodies for the treatment of coronavirus
|
|
US20220332822A1
(en)
|
2021-04-16 |
2022-10-20 |
Tiziana Life Sciences Plc |
Subcutaneous administration of antibodies for the treatment of disease
|
|
KR20240018454A
(ko)
|
2021-05-06 |
2024-02-13 |
주노 테라퓨틱스 게엠베하 |
T 세포의 자극 및 형질도입 방법
|
|
AU2022365121A1
(en)
|
2021-10-14 |
2024-04-18 |
The Brigham And Women's Hospital, Inc. |
Methods of suppressing microglial activation
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4469478A1
(en)
|
2022-01-26 |
2024-12-04 |
Mabswitch Inc. |
Bispecific molecule with tunable affinity to a targetted antigen
|
|
WO2023147510A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Chromatography arrays and related methods and kits
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|
|
WO2024161021A1
(en)
|
2023-02-03 |
2024-08-08 |
Juno Therapeutics Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
CN121127253A
(zh)
|
2023-02-28 |
2025-12-12 |
朱诺治疗学股份有限公司 |
治疗系统性自身免疫性疾病的细胞疗法
|
|
WO2024243340A1
(en)
|
2023-05-23 |
2024-11-28 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2025049254A1
(en)
|
2023-08-25 |
2025-03-06 |
Juno Therapeutics, Inc. |
Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
|
|
WO2025049247A1
(en)
|
2023-08-25 |
2025-03-06 |
Juno Therapeutics, Inc. |
5,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
|
|
WO2025049250A1
(en)
|
2023-08-25 |
2025-03-06 |
Juno Therapeutics, Inc. |
6,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
|
|
WO2025049253A1
(en)
|
2023-08-25 |
2025-03-06 |
Juno Therapeutics, Inc. |
Bridged cycle‑based inhibitors of dna‑dependent protein kinase and compositions and application in gene editing
|
|
WO2025083196A1
(en)
|
2023-10-18 |
2025-04-24 |
Tq Therapeutics Gmbh |
A method of manufacturing a cellular therapy product and respective kits and devices
|
|
US20250241912A1
(en)
|
2024-01-25 |
2025-07-31 |
Juno Therapeutics, Inc. |
Use of bridged cycle-based inhibitors of dna-dependent protein kinase in combination of dna polymerase theta inhibitor and compositions and application in gene editing
|
|
WO2025179188A1
(en)
|
2024-02-22 |
2025-08-28 |
Juno Therapeutics, Inc. |
Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|